Yellow Fever Vaccine
Mostrando 1-12 de 63 artigos, teses e dissertações.
-
1. Qual recomendação para vacinação de febre amarela em crianças com atraso vacinal?
Para crianças vacinadas com a primeira dose da vacina da febre amarela (atenuada) aos 9 (nove) meses de idade, a segunda dose deverá ser administrada até os 4 anos 11 meses e 29 dias de idade. Se a criança possuir 5 anos ou mais de idade, com a primeira dose administrada anteriormente a esta idade, a recomendação é que a dose de reforço seja adm
Núcleo de Telessaúde Mato Grosso do Sul. Publicado em: 12/06/2023
-
2. Existe contraindicação para a vacinação contra a febre amarela em pessoas acima de 60 anos?
Idade acima de 60 de idade não é contraindicação para receber a vacina contra febre amarela (VFA). No entanto, algumas situações e indivíduos têm sido identificados como de maior risco para eventos adversos graves após a vacinação, sendo pessoas com doenças autoimunes independentemente da idade e a primovacinação (primeira vacinação contra
Núcleo de Telessaúde Santa Catarina. Publicado em: 12/06/2023
-
3. Adverse events of the yellow fever vaccine in chronic urticaria: evaluation of patients treated or not with omalizumab compared to healthy individuals
Abstract Background: The ear is a region that has a high prevalence of cutaneous carcinomas and several guidelines indicate Mohs micrographic surgery as the first-choice treatment in such cases. Although the technique allows maximum preservation of healthy tissue, many auricular surgical wounds constitute a challenge due to the peculiar local anatomy, with
An. Bras. Dermatol.. Publicado em: 2021-08
-
4. Generation of Yellow Fever virus vaccine in skeletal muscle cells of chicken embryos
BACKGROUND The Yellow Fever (YF) vaccine is produced by the inoculation of embryonated chicken eggs with YF17DD virus on the ninth day of development. Full embryos are collected on the twelfth day of development for vaccine formulation. Skeletal muscle tissue is the main site where biosynthesis of viral particles occurs. OBJECTIVES This study aimed to an
Mem. Inst. Oswaldo Cruz. Publicado em: 09/12/2019
-
5. Previous dengue or Zika virus exposure can drive to infection enhancement or neutralisation of other flaviviruses
BACKGROUND Dengue virus (DENV) has circulated in Brazil for over 30 years. During this time, one serotype has cyclically replaced the other, until recently, when all four distinct serotypes began to circulate together. Persistent circulation of DENV for long time periods makes sequential infections throughout a person’s life possible. After primary DENV
Mem. Inst. Oswaldo Cruz. Publicado em: 12/08/2019
-
6. Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases
Abstract Background: In Brazil, we are facing an alarming epidemic scenario of Yellow fever (YF), which is reaching the most populous areas of the country in unvaccinated people. Vaccination is the only effective tool to prevent YF. In special situations, such as patients with chronic immune-mediated inflammatory diseases (CIMID), undergoing immunosuppressi
Adv. rheumatol.. Publicado em: 29/07/2019
-
7. Lipase and factor V (but not viral load) are prognostic factors for the evolution of severe yellow fever cases
BACKGROUND Despite a highly efficacious vaccine, yellow fever (YF) is still a major threat in developing countries and a cause of outbreaks. In 2018, the Brazilian state of São Paulo witnessed a new YF outbreak in areas where the virus has not been detected before. OBJECTIVE The aim is to describe the clinical and laboratorial characteristics of severe c
Mem. Inst. Oswaldo Cruz. Publicado em: 20/05/2019
-
8. A vacinação e o saber do adolescente: educação em saúde e ações para a imunoprevenção
Resumo Estudo transversal em interface com a extensão em 22 escolas públicas de Divinópolis, Minas Gerais, Brasil, que compõe 605 adolescentes entre 13 e 18 anos. Teve por objetivo analisar a situação vacinal de adolescentes do 9º ano do ensino fundamental e o conhecimento sobre doenças transmissíveis e as imunopreveníveis. Foi utilizada amostragem
Ciênc. saúde coletiva. Publicado em: 2019-02
-
9. Yellow fever outbreak in Brazil: the puzzle of rapid viral spread and challenges for immunisation
We discuss the complex eco-social factors involved in the puzzle of the unexpected rapid viral spread in the ongoing Brazilian yellow fever (YF) outbreak, which has increased the reurbanisation risk of a disease without urban cases in Brazil since 1942. Indeed, this rapid spatial viral dissemination to the Southeast and South regions, now circulating in the
Mem. Inst. Oswaldo Cruz. Publicado em: 03/09/2018
-
10. Is a dose of 17D vaccine in the current context of Yellow Fever enough?
Braz. J. Microbiol.. Publicado em: 2018-09
-
11. Yellow fever
Summary The yellow fever (YF) virus is a Flavivirus, transmitted by Haemagogus, Sabethes or Aedes aegypti mosquitoes. The disease is endemic in forest areas in Africa and Latin America leading to epizootics in monkeys that constitute the reservoir of the disease. There are two forms of YF: sylvatic, transmitted accidentally when approaching the forests, and
Rev. Assoc. Med. Bras.. Publicado em: 2018-02
-
12. Single shot of 17D vaccine may not confer life-long protection against yellow fever
The yellow fever (YF) vaccine has been used since the 1930s to prevent YF, which is a severe infectious disease caused by the yellow fever virus (YFV), and mainly transmitted by Culicidae mosquitoes from the genera Aedes and Haemagogus . Until 2013, the World Health Organization (WHO) recommended the administration of a vaccine dose every ten years. A new re
Mem. Inst. Oswaldo Cruz. Publicado em: 27/11/2017